Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Is 'nearshoring', the preference among pharma and biotech to move operations to the domestic markets versus outsourcing ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.